General Information of Drug (ID: DMNABMU)

Drug Name
GS-4997 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diabetic nephropathy GB61.Z Phase 2 [1]
Pulmonary arterial hypertension BB01.0 Phase 2 [2]
Cross-matching ID
PubChem CID
71245288
CAS Number
CAS 1448428-04-3
TTD Drug ID
DMNABMU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GS-4977 DMBDFN7 Diabetic nephropathy GB61.Z Phase 2 [3]
PMID23147077C10 DM3Z6F4 Discovery agent N.A. Investigative [4]
MSC2032964A DMS3O9H Discovery agent N.A. Investigative [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis signal-regulating kinase 1 (MAP3K5) TTOQCD8 M3K5_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT02234141) GS-4997 in Adults With Pulmonary Arterial Hypertension. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33.
4 Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7326-9.
5 Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol Med. 2010 Dec;2(12):504-15.